Merck & Co. stock gains as analysts lift price targets on cancer drug progress
Published on 09/11/2026 at 14:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock (ISIN US58933Y1055) is trading around USD 144.71 on the New York Stock Exchange as of September 10, 2026, close to its recent one-year high and after delivering a 75.6% return over the past year, according to Investing.com on September 11, 2026.
Analysts boost Merck & Co. stock targets
According to Investing.com on September 11, 2026, Berenberg raised its price target on Merck & Co. stock to USD 137 from USD 127 while maintaining a Hold rating, citing new cancer drug data.
The same report notes that Merck & Co. stock has gained 75.6% over the past 12 months, trading at USD 144.71 with a market capitalization of about USD 357 billion, underscoring how far the shares have run ahead of Berenberg's updated target, which now sits USD 7.71 below the prevailing price on that date, according to Investing.com.
Beyond Berenberg, Guggenheim lifted its price target for Merck & Co. to USD 170 and kept a Buy rating after positive data from a cancer drug collaboration with Moderna, as reported by Investing.com on September 11, 2026.
The same overview states that Wolfe Research increased its price target for Merck & Co. to USD 180 with an Outperform rating after favorable clinical results for a cancer treatment combination, suggesting that some houses see further upside of around USD 35.29 from the USD 144.71 trading level noted in that report, according to Investing.com.
In contrast, UBS downgraded Merck & Co. from Buy to Neutral with a price target of USD 150, pointing to valuation and recent share performance as the main reasons, placing its target USD 5.29 above the USD 144.71 price level cited in the same report, according to Investing.com.
Q2 2026 earnings and guidance in focus
Merck & Co. last reported quarterly figures for the period ended in the second quarter of 2026, posting revenue of USD 16.61 billion compared with analyst expectations of USD 16.37 billion, which corresponds to an increase of about 5.1% versus the same quarter a year earlier, as summarized by Ad-hoc-news on September 10, 2026.
On the bottom line, Merck & Co. delivered earnings per share of negative USD 0.13 in the second quarter of 2026, beating the consensus estimate of negative USD 0.26 by USD 0.13 per share, according to Ad-hoc-news.
The same reporting notes that Merck & Co. has guided for fiscal year 2026 earnings per share in a range between USD 2.66 and USD 2.76, with sell-side analysts cited in that overview forecasting around USD 2.76 per share for the year, effectively at the upper end of the company’s guidance corridor, as summarized by Ad-hoc-news.
According to MEXC, Merck & Co. generated total sales of USD 16.607 billion in the second quarter of 2026, with its cancer drug franchise Keytruda and related products contributing USD 8.366 billion, an increase of 5% year over year.
The same analysis highlights that WINREVAIR delivered USD 588 million in sales during the second quarter of 2026, representing year-on-year growth of 75%, which underscores how newer therapies are adding incremental revenue on top of the established oncology portfolio, according to MEXC.
In the same quarter, Merck & Co. reported a GAAP loss per share of USD 0.54 and a non-GAAP loss per share of USD 0.13, figures that include a USD 2.31 per share charge related to the acquisition of Terns Pharmaceuticals, indicating that deal-related costs weighed heavily on reported earnings, as detailed by MEXC.
The combination of a 5.1% increase in quarterly revenue to USD 16.61 billion and strong growth in key products like WINREVAIR, up 75% year on year, supports Merck & Co.'s decision to raise its full-year 2026 sales forecast to a range of USD 66.3 billion to USD 67.3 billion, according to MEXC.
Valuation and dividend considerations
Based on data compiled by MarketBeat through September 11, 2026, Merck & Co. stock carries a consensus rating of Moderate Buy, with an average target price of USD 151.32 and valuation metrics that include a price-to-earnings ratio of 115.75 and a price-to-earnings-growth ratio of 6.42.
The same MarketBeat overview indicates that Merck & Co. shares have a 52-week low of USD 77.58 and a 52-week high of USD 156.92, implying that the USD 144.71 price level reported by Investing.com on September 10, 2026, stands roughly USD 67.13 above the one-year low and USD 12.21 below the one-year high, according to MarketBeat.
Merck & Co. also continues to return cash to shareholders, with a quarterly dividend of USD 0.85 per share that corresponds to an annualized payout of USD 3.40 and a dividend yield of about 2.3% at prevailing share prices, as reported by MarketBeat on September 11, 2026.
The same filing-based summary notes that this dividend equates to a payout ratio of around 272%, which reflects the depressed GAAP earnings in recent quarters due to acquisition-related charges and indicates that cash distributions are presently covered by adjusted profit metrics and cash flow rather than headline net income, according to MarketBeat.
Merck & Co. stock near upper end of 52-week range
Per data compiled by Upstox, Merck & Co. stock traded at USD 144.69 on the New York Stock Exchange as of September 11, 2026, during a session in which the price moved between an intraday low of USD 144.14 and an intraday high of USD 147.70, with an average price of USD 145.92 and a market capitalization of about USD 362.00 billion in that snapshot.
Key data on Merck & Co. stock
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Trading venue: NYSE
- Price (as of September 11, 2026): 144.69 USD
- Market capitalization: 362,000,000,000 USD (as of September 11, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
